NOC:NYSENorthrop Grumman Corporation Analysis

Northrop Grumman is trading at $545.85, just below its 20‑day SMA of $549.34 and comfortably above the 50‑day SMA of $601.17, signaling short‑term weakness. The 14‑day RSI of 41 suggests the stock is not oversold, while a positive MACD histogram hints at tentative bullish momentum despite a broader bearish trend. Current price remains above the identified support level of $525.73 but under the resistance of $563.93, leaving limited upside in the near term. A DCF‑derived fair value of roughly $123 starkly contrasts with the market price, flagging the equity as significantly overvalued on a fundamentals basis. The forward PE of 18.1 is well below the industry average PE of 30.5, underscoring a relative value edge despite the price premium.
The company delivers solid fundamentals, with 4.4% revenue growth, a 28.5% ROE and a healthy free cash flow of $2.07 bn supporting a 1.72% dividend yield. A modest payout ratio of 29% makes the dividend appear sustainable. Volatility over the past 30 days sits at 24%, and beta is near zero, reflecting low market‑wide sensitivity but elevated stock‑specific swings. Analyst sentiment remains positive, with a “Buy” consensus and a median price target near $691, though Jefferies recently trimmed its target to $620, tempering enthusiasm. The defense sector’s stable government contracts provide a defensive moat, while recent announcements of new space‑navigation capabilities could fuel future growth. Given the overvalued price relative to intrinsic estimates, we recommend a cautious short‑term stance, a neutral medium‑term view, and a long‑term buy for investors seeking exposure to a high‑ROE, dividend‑paying defense champion.